Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine

In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group.
After a thorough evaluation, EMA’s human medicines committee (CHMP) concluded by consensus that the data on the vaccine were robust and met the criteria for efficacy, safety and quality.